DeğerQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSatış/genel/idari giderler4.1 M4.26 M3.94 M3.4 M5.54 M17.14 MAraştırma ve geliştirme845 K988 K852 K550 K641 K3.03 MFaaliyet karı-2.23 M-3.44 M-3.98 M-1.4 M-4.51 M-13.33 MFaaliyet Dışı Gelir, Toplam-1.18 M549 K1.27 M-19 K-165 K1.63 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)59 K72 K65 K18 K154 K309 KFaaliyet Dışı Gelir (Faiz Giderleri Hariç)-1.24 M483 K1.21 M-32 K-312 K1.35 MOlağandışı gelirler/giderler1 000-6 000-8 000-5 000-7 000-26 KVergi öncesi kar-11.33 M-2.96 M-2.77 M-1.44 M-11.7 M-18.87 MKazançlardaki özsermayeler——————Vergiler————49 K—Kontrol gücü olmayan/azınlık payı——————Vergi sonrası diğer gelirler/giderler——————Durdurulan faaliyetler öncesi net kar-3.41 M-2.89 M-2.71 M-1.42 M-4.67 M-11.7 MDurdurulan faaliyetler——————Net kar-3.41 M-2.89 M-2.71 M-1.42 M-4.67 M-11.7 MSeyreltme ayarlaması—00000İmtiyazlı temettüler—226 K000226 KAdi hisse senedi sahiplerine düşen seyreltilmiş net kar-3.41 M-3.12 M-2.71 M-1.42 M-4.67 M-11.92 MTemel hisse başına kazanç (Temel EPS)-1.88-1.8-1.24-0.54-1.33-4.91Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)-2.54-1.8-1.24-0.54-1.33-4.91Dolaşımdaki ortalama adi hisse senedi sayısı1.34 M1.69 M2.18 M2.62 M2.43 M8.91 MDolaşımdaki seyreltilmiş hisse senedi sayısı1.34 M1.69 M2.18 M2.62 M2.43 M8.91 MFAVÖK-1.83 M-3.06 M-3.6 M-1.03 M-4.06 M-11.75 MFVÖK-2.23 M-3.44 M-3.98 M-1.4 M-4.51 M-13.33 MGelir maliyeti2.38 M1.57 M1.24 M1.68 M1.47 M5.95 MSatılan malların diğer maliyeti——————Amortisman ve itfa (nakit akışı)398 K378 K377 K367 K451 K1.57 M
Ekso Bionics Holdings Inc
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community.